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Abstract
The pandemic of coronavirus disease (COVID)-2019 has been affected many people all around the world. Patients 
with mental disorders are not as safe as others; also, they might be more vulnerable in such situations. These 
patients take various medications, which can lead to numerous drug-drug interactions with experimental drugs 
uses against COVID-19. According to the potential critical interactions, we reviewed the reputable databases to 
find the interactions between main categories of psychiatric medications (e.g., antidepressants, anti-psychotics, 
sedative/hypnotics, and mood stabilizers) when used in concomitant with COVID-19 experimental agents (e.g., 
hydroxychloroquine, lopinavir/ritonavir, atazanavir, and chloroquine). We hope the list provided in this review 
helps the clinical care staff in treating patients with mental illness infected with severe acute respiratory syndrome 
coronavirus 2 during the COVID-19 pandemic.
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Introduction
Coronavirus disease 2019 (COVID-19) was 
first reported from Wuhan, China, in December 2019 [1] 
and rapidly spread worldwide to become a pandemic on 
March 12, 2020 [2]. No specific drug has been approved 
for the treatment of COVID-19 yet. Infectious Diseases 
Society of America has suggested a few agents based 
on limited clinical trials such as hydroxychloroquine 
(HCQ) and lopinavir/ritonavir (LPV/r) [3]. Atazanavir 
(ATV) also has been supported by other documents to 
have a potential benefit for COVID-19 [4], [5].
Mental disorders are listed among the most 
common causes of chronic diseases. The prevalence 
was estimated to be 22.1% in 2019 [6]. This group of 
patients is not as safe as others; also, they might be 
more vulnerable in such situations [7], [8] due to probable 
cognitive impairment, lack of awareness regarding 
transmission risks, and poor personal hygiene [9]. The 
presence of comorbidities, such as mental disorders 
in patients with COVID-19, makes the treatment plan 
more challenging [10]. One of these challenges is drug-
drug interaction.
Ritonavir applies a paradoxical inhibitory/
induction effect on cytochromes P450 (CYP) family 
3, subfamily A (CYP3A) isoenzyme and is a moderate 
inhibitor against CYP2D6 isoenzyme [11]. ATV is a 
substrate and inhibitor of CYP isoenzyme 3A and 
inhibits/induces P-glycoprotein [12]. Therefore, these 
two medications have many significant drug interactions 
that may affect the outcome of patients. HCQ and 
chloroquine (CQ) are highly potential to prolong QT 
interval and may elevate the adverse effects of drugs 
in this direction [13].
Thus, we aimed to evaluate the interactions 
between psychiatric medications (consist of 
antidepressants, anti-psychotics, sedative/hypnotics, 
and mood stabilizers) and highly used experimental 
COVID-19 treatments including HCQ, CQ, LPV/r, 
and ATV, to help the clinician decisions in choosing 
appropriate medications with lowest drug-drug 
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interactions according to the underlying disease of 
patients.
Materials and Methods
We studied four reputable databases of 
drug interactions including Lexi-Interact [14], Drug 
Interactions Checker [15], UpToDate [16], HIV drug 
interactions [17], as well as Stockley’s Drug Interactions 
Pocket Companion and AIDS info guidelines for the 
use of antiretroviral agents in adults and adolescents 
with HIV [18] to find out the interactions between four 
categories of psychiatric medications and experimental 
COVID-19 medications. Additional references (e.g., 
original articles and FDA drug information) were also 
included as needed.
Results
Concise and rapid guidance for drug-drug 
interactions is presented in Table 1. In this table, the 
green color illustrates no clinically significant interaction, 
the yellow color mentions the need for monitoring 
or treatment modification, the red color represents 
contraindication of combination, and the blue color is used 
to demonstrate controversy among recommendations 
of different databases. The detailed information about 
the mechanism of interaction, consequences, and 
management were reviewed in this section.
Antidepressants
Citalopram/escitalopram
Citalopram/escitalopram is metabolized through 
CYP2C19, CYP2D6, and CYP3A4 isoenzymes [16].
Citalopram/escitalopram – HCQ/CQ
Mechanism and consequence
Both selective serotonin reuptake 
inhibitors (SSRIs) and HCQ/CQ may lead to QT 
prolongation [14], [15], [19] and hypoglycemia [14]. 
Concomitant use of these medications enhances such 
side effects.
Table 1: Rapid drug interactions guidance
Psychiatric medications Experimental agents for COVID-19
Drug category Drugs name Hydroxychloroquine Chloroquine Lopinavir+Ritonavir Atazanavir
Antidepressants Citalopram 1.1.1 1.1.1 1.1.2 1.1.2
Escitalopram 1.1.1 1.1.1 1.1.2 1.1.2
Fluoxetine 1.2.1 1.2.1 1.2.2 1.2.3
Fluvoxamine 1.3.1 1.3.1 1.3.2 1.3.3
Paroxetine 1.4.1 1.4.2 1.4.3 1.4.4
Sertraline 1.5.1 1.5.1 1.5.2 1.5.3
Venlafaxine 1.6.1 1.6.1 1.6.2 1.6.2
Duloxetine 1.7.1 1.7.1 1.7.2 1.7.2
Amitriptyline 1.8.1 1.8.1 1.8.2 1.8.2
Maprotiline 1.8.1 1.8.1 1.8.2 1.8.2
Nortriptyline 1.8.1 1.8.1 1.8.2 1.8.2
Desipramine 1.8.1 1.8.1 1.8.2 1.8.2
Doxepin 1.9.1 1.9.1 1.9.2 1.9.2
Clomipramine 1.10.1 1.10.1 1.10.2 1.10.2
Imipramine 1.10.1 1.10.1 1.10.2 1.10.2
Bupropion 1.11.1 1.11.2 1.11.3 1.11.4
Buspirone 1.12.1 1.12.1 1.12.2 1.12.2
Mirtazapine 1.13.1 1.13.1 1.13.2 1.13.2
Trazodone 1.13.1 1.13.1 1.13.2 1.13.2
Anti-psychotics Aripiprazole 2.1.1 2.1.1 2.1.2 2.1.3
Clozapine 2.2.1 2.2.1 2.2.2 2.2.2
Olanzapine 2.3.1 2.3.1 2.3.2 2.3.3
Quetiapine 2.4.1 2.4.1 2.4.2 2.4.2
Risperidone 2.5.1 2.5.1 2.5.2 2.5.3
Chlorpromazine 2.6.1 2.6.1 2.6.2 2.6.3
Fluphenazine 2.6.1 2.6.1 2.6.2 2.6.3
Perphenazine 2.6.1 2.6.1 2.6.2 2.6.3
Thioridazine 2.6.1 2.6.1 2.6.2 2.6.3
Haloperidol 2.7.1 2.7.1 2.7.2 2.7.2
Pimozide 2.8.1 2.8.1 2.8.2 2.8.2
Sedative hypnotics Alprazolam 3.1.1 3.1.1 3.1.2 3.1.3
Chlordiazepoxide 3.1.1 3.1.1 3.1.2 3.1.3
Clonazepam 3.1.1 3.1.1 3.1.2 3.1.3
Diazepam 3.1.1 3.1.1 3.1.2 3.1.3
Temazepam 3.2 3.2 3.2 3.2
Lorazepam 3.2 3.2 3.2 3.2
Oxazepam 3.2 3.2 3.2 3.2
Triazolam 3.3.1 3.3.1 3.3.2 3.3.2
Midazolam 3.3.1 3.3.1 3.3.2 3.3.2
Zolpidem 3.4.1 3.4.1 3.4.2 3.4.2
Mood stabilizers Carbamazepine 4.1.1 4.1.2 4.1.3 4.1.4
Valproic acid 4.2.1 4.2.2 4.2.3 4.2.4
Lithium 4.3.1 4.3.1 4.3.1 4.3.2
Lamotrigine 4.4.1 4.4.2 4.4.3 4.4.4
Red color: Extremely significant interaction. Contraindicated. Yellow color: Minimally or moderately significant interaction. Monitoring or therapy modification is needed. Blue color: Controversy between different references. 
Green color: No significant interaction or does not require any action. The paragraph number is cited in the table, Ctrl + Click on paragraph number to refer to the related section of the article for additional information.
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Management
It is recommended to use caution in the elderly, 
females, individuals with a history of cardiovascular 
disease, hypokalemia, and hypomagnesemia. Close 
monitoring for QT prolongation and hypoglycemia is 
required [14], [15].
Citalopram/escitalopram – LPV/r and ATV
Mechanism and consequence
Coadministration of either LPV/r or ATV with 
citalopram/escitalopram is associated with increased 
serum concentrations of these medications and QT 
prolongation effects [17], [18], [19].
Management
It is recommended to initiate SSRIs with the 
lowest dose and titrate slowly. Regular electrocardiogram 
(ECG) monitoring and correcting electrolyte 
abnormalities (hypokalemia or hypomagnesemia) 
may be required, especially in patients with a previous 
history of cardiovascular disease or electrolyte 
abnormalities [15], [17], [18].
Fluoxetine
Fluoxetine is a significant substrate of CYP2C9 
and CYP2D6 isoenzymes [16].
Fluoxetine – HCQ/CQ
The interactions are similar to those mentioned 
for citalopram/escitalopram (Refer to 1.1.1).
Fluoxetine – LPV/r
Mechanism and consequence
Inhibitory effect of LPV/r on the CYP2D6 
isoenzyme is predicted to raise the serum concentration 
of fluoxetine. Furthermore, fluoxetine can increase 
ritonavir [15], [17], [19], [20]. Serotonin syndrome is 
reported in a case series of patients that used ritonavir-
based HAART with fluoxetine [21]. On the other hand, 
decreased concentrations of fluoxetine were observed 
when combined with ritonavir-boosted protease 
inhibitors (PIs) [22].
Management
Careful monitoring of adverse effects and dose 
adjustment for fluoxetine may be needed [15], [17], 
[18], [22].
Fluoxetine – ATV
There are no clinically significant 
interactions [14], [15], [17], [22].
Fluvoxamine
Fluvoxamine is mainly metabolized through 
the CYP2D6 isoenzyme [16].
Fluvoxamine – HCQ/CQ
Mechanism and consequence
SSRIs may increase insulin sensitivity 
and enhance the hypoglycemic effects of HCQ/
CQ [14]. Moreover, a study reports an increase in the 
concentrations of HCQ/CQ [19], while two others do not 
mention any significant interactions [15], [22].
Management
Monitor for the hypoglycemic effects of 
medications is required [14].
Fluvoxamine – LPV/r
Mechanism and consequence
Coadministration has not been studied. LPV/r 
could potentially increase fluvoxamine concentrations 
by the inhibitory effect of ritonavir on the CYP2D6 
isoenzyme [17], [19].
Management
No dosage adjustment is recommended [17]. 
However, according to another reference, consideration 
of an alternative antidepressant may be needed [23].
Fluvoxamine – ATV
No clinically significant interactions were found 
[14], [15], [17], [19], [22].
Paroxetine
Paroxetine is a major substrate for CYP2D6 
isoenzyme [16].
Paroxetine – HCQ
Interactions are similar to those of fluvoxamine 
(Refer to 1.3.1).
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Paroxetine – CQ
Mechanism and consequence
Paroxetine concentrations may rise following 
inhibition of CYP2D6 isoenzyme [14], [19].
Management
Monitor for increased drug effects, and 
hypoglycemia is recommended [14].
Paroxetine – LPV/r
Mechanism and consequence
LPV/r can increase the serum concentration 
of paroxetine due to the inhibitory effect of ritonavir on 
the CYP2D6 isoenzyme [15], [17], [18], [22]. Moreover, 
decreased paroxetine concentrations are reported with 
ritonavir-boosted PIs [22].
Management
Monitoring of adverse effects and probably 
dose adjustment of paroxetine may be required [15], 
[17], [18], [22].
Paroxetine – ATV
Mechanism and consequence
Interactions are controversial among different 
studies. Some references mention that there is no 
significant interaction [14], [15], while some others point 
to the same interaction that exists for LPV/r (refer to 
1.4.3) [17], [18].
Management
As mentioned for LPV/r (refer to 1.4.3) [17], [18].
Sertraline
Sertraline is a minor substrate for CYP2B6, 
CYP2C9, CP2C19, and CYP3A4 isoenzymes [16].
Sertraline – HCQ/CQ
Refer to citalopram/escitalopram (1.1.1) [14], [15).
Sertraline – LPV/r
Mechanism and consequence
LPV/r may decrease the sertraline 
concentration through induction of CYP2B6, CYP2C9, 
and CP2C19 isoenzymes [17], [19], [22].
Management
Monitoring for the efficacy of sertraline and 
dose titration may be required [17], [22].
Sertraline – ATV
Mechanism and consequence
Sertraline exposure may increase by inhibition 
of CYP3A4 isoenzyme [17], [19], [24].
Management
Dose adjustment may not be required [17].
Venlafaxine
Venlafaxine – HCQ/CQ
Mechanism and consequence
Although some references did not report 
any interactions [14], [22], studies reported that both 
medications could prolong the QT interval [15], [19].
Management
Monitoring QT interval and correction of 
hypokalemia and hypomagnesemia may be necessary 
[15], [19].
Venlafaxine – LPV/r and ATV
Mechanism and Consequence
Venlafaxine concentration may be increased 
if either ATV or LPV/r is simultaneously administered 
through an inhibitory effect on the CYP3A4 isoenzyme 
[15], [17], [19], [24].
Management
Dose adjustment is not required, but it is 
recommended to use it with caution [15], [17], [24].
Duloxetine
Duloxetine is a major substrate of CYP1A2 
and a minor substrate of CYP2D6 isoenzymes [16].
Duloxetine – HCQ/CQ
Mechanism and consequence
Plasma concentrations of duloxetine may 
be elevated through inhibitory effects on CYP2D6 
isoenzyme [14], [15], [19].
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Management
Monitor for adverse reactions and adjust the 
dose, if needed [14], [15].
Duloxetine – LPV/r and ATV
Ritonavir induces CYP1A2 and inhibits 
CYP2D6 isoenzymes; thus, the consequence of 
interaction is unpredictable, and dose adjustment 
may not be essential. ATV does not significantly affect 
duloxetine concentrations [15], [17], [19], [24].
Amitriptyline/nortriptyline/maprotiline/
desipramine
These tricyclic antidepressants (TCAs) are 
major substrates of CYP2D6 isoenzyme [16].
Amitriptyline/Nortriptyline/Maprotiline/
Desipramine – HCQ/CQ
Mechanism and consequence
Coadministration of two medications with QT 
prolongation effects causes additive adverse effects, 
including torsade de pointes arrhythmias [15].
Management
Correction of risk factors (e.g., hypokalemia 
and hypomagnesemia) and ECG monitoring may be 
required [15]. Some references mention that there is no 
need for taking action [14], [22].
Amitriptyline/Nortriptyline/Maprotiline/
Desipramine – LPV/r and ATV
Mechanism and consequence
The serum concentration of the TCAs may 
be increased with the administration of LPV/r due to 
inhibitory effects on CYP2D6 isoenzyme [14], [18], 
[19], [22], [24]. However, it seems that unboosted ATV 
does not have this inhibitory effect, and enhanced TCA 
plasma concentrations are not expected [17].
Management
Monitor for adverse effects of TCAs, and 
dose reduction may be implemented in the case of 
coadministration with LPV/r. Furthermore, monitor for 
decreased effects of TCAs if the LPV/r is discontinued. 
EKG monitoring is also recommended for concomitant 
administration of LPV/r or ATV with mentioned TCAs, 
due to QT prolongation [14], [17], [18], [19].
Doxepin
Doxepin – HCQ/CQ
Use with caution is recommended due to QT 
prolongation, as mentioned in ‎the 1.8.1 section [14], 
[15].
Doxepin – LPV/r and ATV
The mechanism and consequence of 
interaction are the same as other TCAs in 1.8.2 
section. However, the management, in this case, 
is controversial; some studies recommended 
careful monitoring of adverse effects, and a 
decrease in the dose of doxepin may be required 
[14], [15], [18], [22], [24]. In contrast, others believe 
that no dose adjustment is needed [17], [19].
Imipramine/clomipramine
These TCAs are metabolized through CYP2D6, 
CYP2C19, and CYP1A2 isoenzymes [16].
Imipramine/Clomipramine – HCQ/CQ
Monitor for QT interval prolongation, as 
mentioned for other TCAs (section 1.8.1).
Imipramine/Clomipramine – LPV/r and ATV
Mechanism and consequence
Both LPV/r and ATV may increase the serum 
concentration of mentioned TCAs due to inhibitory 
effects on the CYP450 isoenzymes [14], [15], [17], [18], 
[19], [22], [24].
Management
Close monitoring of adverse effects, including 
QT prolongation, is recommended. Furthermore, a 
decrease in the dose of TCAs may be required [14], 
[15], [17], [18], [22].
Bupropion
Bupropion is a major substrate of CYP2B6 
isoenzyme [16].
Bupropion – HCQ
No clinically significant interaction was reported 
[14], [15], [22].
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Bupropion - CQ
Mechanism and consequence
Bupropion is a potent inhibitor of CYP2D6 
isoenzyme and increases CQ exposure [14]. On the 
other hand, bupropion applies the dose-dependent 
risk of seizures, mostly when used concomitantly with 
medications that decrease the threshold of seizures 
(e.g., CQ) [15].
Management
Both medications should be initiated with lower 
doses and titrate slowly based on clinical response. If 
seizures occur during treatment with bupropion, the 
drug should be discontinued permanently [15].
Bupropion – LPV/r
Mechanism and consequence
LPV/r reduces the area under curve (AUC) of 
bupropion by 57% [14], [15], [17], [18], [19], [22], [24], [25]. 
It seems that the induction of CYP2B6 isoenzyme by 
ritonavir leads to this interaction, contrary to in vitro data, 
which reports inhibition of CYP2B6 by ritonavir [14], [26].
Management
The efficacy of bupropion treatment should 
be monitored. Initiating therapy with higher doses is 
not recommended, but titration of bupropion dose is 
suggested based on clinical response [14], [15], [17], 
[18], [22].
Bupropion – ATV
There is no clinically significant interaction [14], 
[15], [17], [18], [19], [22].
Buspirone
Buspirone is metabolized mainly through the 
CYP3A4 pathway [16].
Buspirone – HCQ/CQ
No significant interactions were found [14], 
[15], [22].
Buspirone – LPV/r and ATV
Mechanism and consequence
Inhibitors of CYP3A4 isoenzyme increase the 
plasma concentrations of buspirone and may lead to 
Parkinson-like symptoms [14], [15], [17], [18], [22].
Management
It is recommended to initiate therapy with the 
lowest dose of buspirone and titrate based on clinical 
response followed by monitoring adverse reactions 
[14], [15], [17], [18], [22].
Mirtazapine/trazodone
Mirtazapine/trazodone – HCQ/CQ
There is no particular recommendation in this 
regard. Some references did not report a significant 
interaction [14], [22], but others have focused on the 
risk of QT prolongation and recommend using caution 
in susceptible patients [15], [19].
Mirtazapine/Trazodone – LPV/r and ATV
Mechanism and consequence
Either LPV/r or ATV can increase the serum 
concentrations of mirtazapine/trazodone [14], [15], [17], 
[19], [22], [24] through inhibition of CYP3A4 isoenzyme 
[14], [17].
Management
It is recommended to initiate therapy with 
lower doses and monitor increased central nervous 
system adverse effects and QT prolongation [14], 
[15], [17], [22].
Anti-psychotics
Aripiprazole
Aripiprazole is mainly metabolized through 
CYP2D6 and CYP3A4 isoenzymes [16].
Aripiprazole – HCQ/CQ
Mechanism and consequence
The risk of clinically significant QT prolongation 
is not definite [15].
Management
No action is needed [14], [22]. According 
to some references, QT prolongation may occur in 
patients with underlying cardiovascular disease or 
concomitant use of medications, which cause QT 
prolongation [15], [19], and close ECG monitoring may 
be required [15].
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Aripiprazole – LPV/r
Mechanism and consequence
LPV is a potent inhibitor of CYP 3A4, and 
ritonavir is a strong inhibitor of CYP3A4 and CYP2D6 
isoenzymes. Thus, increased plasma concentrations of 
aripiprazole are anticipated [14], [22], [24]. Besides, QT 
prolongation may occur, but it is uncertain [15], [19].
Management
Pharmacological responses should be 
monitored. Up to 75% dose reduction for aripiprazole 
may be needed [14], [18]. ECG monitoring is 
recommended based on some references [15], [19].
Aripiprazole – ATV
Mechanism and consequence
ATV inhibits the CYP3A4 pathway and may 
increase the plasma concentration of aripiprazole [14], 
[15], [17], [24].
Management
Aripiprazole dose reduction may be required 
up to 50% [14], [15], [17], [18], [22]. Consider up to 
75% dose reduction if concomitant CYP2D6 isoenzyme 
inhibitors are used [14].
Clozapine
Clozapine is a major substrate of CYP1A2 and 
a minor substrate of CYP3A4 and CYP2D6 isoenzymes.
Clozapine – HCQ/CQ
Mechanism and consequence
Both clozapine and antimalarial medications 
have similar adverse effects such as QT interval 
prolongation and agranulocytosis, which may increase 
concomitant use of these medications [14], [15].
Management
Use with caution and monitor for adverse 
reactions. Discontinue treatment if the QT interval 
increased more than 500 milliseconds (ms). Modifiable 
risk factors (e.g., hypokalemia and hypomagnesemia) 
should be corrected [14], [15].
Clozapine – LPV/r and ATV
Mechanism and consequence
Clozapine plasma concentrations may be 
increased [14], [15], [17], [18], [19], [22] through 
inhibitory effects of LPV/r and ATV on hepatic 
isoenzymes [14], [17].
Management
Clozapine should be initiated with lower 
doses and titrate gradually with monitoring adverse 
reactions (e.g., QT prolongation) [14], [15], [17], [18], 
[24]. Some references suggest avoiding concomitant 
use of LPV/r with clozapine due to severe hematologic 
side effects [22].
Olanzapine
Olanzapine is a major substrate of CYP1A2 
and a minor substrate of CYP2D6 isoenzyme [16].
Olanzapine – HCQ/CQ
Mechanism and consequence
Some references mention that QT prolongation 
could occur in high-risk patients [14], [15].
Management
Close ECG monitoring and modifying risk 
factors may be helpful [14], [15]. One reference does 
not indicate this interaction [19].
Olanzapine – LPV/r
Mechanism and consequence
Ritonavir induces CYP1A2 isoenzyme 
and leads to decreased (up to 50%) olanzapine 
concentrations [14], [15], [17], [19], [22], [23], [24], 
[27].
Management
Close monitoring for the efficacy of 
olanzapine and dose adjustment may be required 
[14], [15], [17], [22]. Furthermore, some references 
advise monitoring QT intervals in high-risk 
populations [15].
Olanzapine – ATV
There are no clinically significant interactions 
[14], [15], [17], [19], [22].
Quetiapine
Quetiapine is mainly metabolized through 
CYP3A4 hepatic isoenzyme [16].
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Quetiawpine – HCQ/CQ
As mentioned for olanzapine – HCQ/CQ (Refer 
to 2.3.1) [14], [15], [19]. Furthermore, due to additive 
hypoglycemic effects of concomitant QC administration, 
one reference advices to monitor for hypoglycemia [14].
Quetiapine – LPV/r and ATV
Mechanism and consequence
PIs increase the AUC of quetiapine (up to 6 
times) by inhibiting CYP3A4 isoenzyme.
Management
Some references recommend avoiding 
coadministration [17], [19]; however, some recommend 
using lower doses of quetiapine. Initiate with the lowest 
dose of quetiapine and titrate gradually based on 
the adverse effects and efficacy of the medication. If 
the patient is stable on a specific dose of quetiapine, 
it is recommended to reduce the dose by 1/6, if PI is 
required. Monitor for adverse effects, including QT 
prolongation [14], [15], [18], [22], [23], [24].
Risperidone
Risperidone is a major substrate of CYP2D6 
and CYP3A4 isoenzymes and P-glycoprotein/ABCB1.
Risperidone – HCQ/CQ
The same as olanzapine (Refer to 2.3.1) [14], 
[15], [19], [22].
Risperidone – LPV/r
Mechanism and consequence
LPV/r increases risperidone exposure 
through inhibitory effects on CYP2D6 isoenzyme and 
P-glycoprotein/ABCB1 [14], [15], [17], [19], which may 
cause risperidone dependent adverse effects including 
extrapyramidal syndrome and neuroleptic malignant 
syndrome [17], [22]. Furthermore, dose-dependent QT 
interval prolongation may occur [14], [15], [17], [22].
Management
Decreased risperidone dose and monitoring 
for adverse drug reactions are required [14], [15], [17], 
[18], [22].
Risperidone – ATV
Some references indicate the same 
interactions that mentioned about LPV/r (refer 
to 2.5.2) [17], [18], [19], but others declare no 
interactions between risperidone and ATV [14], [15], 
[22].
Chlorpromazine/fluphenazine/
perphenazine/thioridazine
These medications are metabolized mainly 
through CYP2D6 isoenzyme [16].
Chlorpromazine/fluphenazine/perphenazine/
thioridazine – HCQ/CQ
Mechanism and Consequence
In addition to the QT prolongation effect, 
which was mentioned for other anti-psychotics, anti-
malaria agents could increase the concentrations of 
phenothiazine-based anti-psychotics by an unknown 
mechanism [14], [19].
Management
Monitoring for side effects (e.g., QT 
prolongation) and modifying underlying risk factors 
should be considered [14], [15], [19].
Chlorpromazine/fluphenazine/perphenazine/
thioridazine – LPV/r
Mechanism and consequence
LPV/r could potentially increase plasma 
concentrations of these anti-psychotics. Additive QT 
interval prolongation may occur in coadministration 
[14], [15], [17], [19].
Management
Use with caution as stated for CQ and HCQ 
(refer to 0) [14], [15], [17], [19].
Chlorpromazine/fluphenazine/perphenazine/
thioridazine – ATV 
There are inconclusive data. Some 
references report no interactions [14], [15]; 
however, one reference remarks QT prolongation in 
coadministration and recommends close monitoring 
in this regard [17].
Haloperidol
Haloperidol has a complex pathway of 
metabolism, including glucuronidation, oxidation, 
CYP3A4, and CYP2D6 isoenzymes mediated reactions 
[16], [17].
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Haloperidol – HCQ/CQ
Mechanism and Consequence
Concomitant administration of two medications 
with QT interval prolongation may have additive side 
effects and lead to serious cardiac arrhythmias. This 
interaction is more frequent when higher doses or 
intravenous haloperidol is administered [14], [15], [19].
Management
Close monitoring for adverse reactions and 
correcting modifiable risk factors such as electrolyte 
abnormalities are necessary [14], [15].
Haloperidol – LPV/r and ATV
Mechanism and consequence
LPV/r and ATV increase haloperidol exposure 
by inhibition of CYP2D6 and CYP3A4 isoenzymes, 
which may lead to increased adverse effects such as 
QT prolongation [14], [15], [17], [24].
Management
Use caution and monitor as mentioned for 
HCQ and CQ (Refer to 2.7.1) [14], [15], [17].
Pimozide
Pimozide is metabolized through CYP3A4 
isoenzyme.
Pimozide – HCQ/ CQ
Mechanism and Consequence
QT interval prolongation is the main interaction, 
as mentioned for concomitant use of other anti-
psychotics with other medications that have the same 
effect [14], [15], [19].
Management
Most of the references advise to avoid 
coadministration of CQ [14], [15], but there are 
controversial recommendations regarding HCQ. One 
database recommends avoidance [15]; however, 
another one suggests not taking any action [14], and 
the other reference advises monitoring for adverse 
effects [19].
Pimozide – LPV/r and ATV
Concomitant use of pimozide with PIs is 
contraindicated due to increased pimozide levels by 
CYP3A4 isoenzyme inhibitory effects of PIs. Increased 
exposure to pimozide may lead to lethal cardiac 
arrhythmias [14], [15], [17], [18], [19], [22], [24].
Sedative/Hypnotics
Alprazolam/chlordiazepoxide/clonazepam/
diazepam
These medications are major substrates of 
CYP 3A4 isoenzyme [16].
Alprazolam/Chlordiazepoxide/Clonazepam/
Diazepam – HCQ/CQ
There are no clinically significant interactions 
[14], [15], [19], [22].
lprazolam/Chlordiazepoxide/Clonazepam/
Diazepam – LPV/r
Mechanism and Consequence
LPV/r may increase the plasma concentrations 
of mentioned benzodiazepines by inhibiting the CYP3A4 
pathway [14], [15], [17], [28].
Management
Monitor for increased adverse reactions of 
benzodiazepines and reduce medication dose if needed, 
especially in the initiation of therapy. It is recommended 
to use alternative benzodiazepines with less probable 
interactions such as lorazepam, oxazepam, and 
temazepam [14], [15], [17], [18], [23]. There are conflicting 
data regarding the coadministration of diazepam and 
ritonavir. Some references recommended avoiding 
this combination, but most of them recommended 
monitoring, dose adjustment, or using alternative 
medications when ritonavir is used as a booster (e.g., 
LPV/r) [17], [22], [23].
Alprazolam/Chlordiazepoxide/Clonazepam/
Diazepam – ATV
Mechanism and consequence
ATV may increase the serum concentrations of 
these benzodiazepines, but there is no ample clinical 
evidence [14], [17], [18], [19].
Management
As stated for LPV/r [14], [17], [18].
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Temazepam/lorazepam/oxazepam
These medications are metabolized through 
non-CYP450 hepatic pathways [16]; thus, there are no 
clinically significant interactions with HCQ, CQ, LPV/r, 
and ATV [14], [15], [16], [17], [18], [19].
Triazolam/midazolam
Triazolam/midazolam – HCQ/CQ
No clinically significant interaction was reported 
[14], [15], [19], [22].
Triazolam/Midazolam – LPV/r and ATV
Mechanism and consequence
LPV/r inhibits CYP3A4 isoenzyme; therefore, 
the concentrations of mentioned benzodiazepines are 
increased, which may lead to respiratory failure [14], 
[15], [17], [18], [19], [23], [29].
Management
The administration of triazolam/oral midazolam 
should be avoided. The parental form of midazolam 
could be used with caution and reduced dose [14], [15], 
[17], [18], [19].
Zolpidem/zopiclone
These medications are mainly metabolized 
through CYP3A4 isoenzyme [16].
Zolpidem/Zopiclone – HCQ/CQ
No clinically significant interaction was reported 
[14], [15], [19], [22].
Zolpidem/Zopiclone – LPV/r and ATV
Mechanism and consequence
Increased sedation may occur due to inhibition 
of CYP3A4 isoenzyme. 
Management
Patients should be monitored closely. Reducing 
the dose of zolpidem/zopiclone may be required [14], 
[15], [17], [18], [19], [29].
Mood stabilizers
Carbamazepine
Carbamazepine is a strong CYP3A4 isoenzyme 
inducer [16].Carbamazepine – HCQ
No clinically significant interaction was 
found [14], [15]; however, according to one reference, 
this combination should be avoided [19].
Carbamazepine – CQ
Mechanism and consequence
Carbamazepine may decrease the plasma 
concentration of CQ through CYP3A4 pathway 
induction [14], [15]. CQ-induced seizures have been 
reported [15], [16].
Management
Monitor for decreased effects of CQ [14] 
and use with caution in patients with a history of 
seizure [15], [16]. One reference recommended 
avoiding combination [19].
Carbamazepine – LPV/r
Mechanism and consequence
Carbamazepine may decrease the LPV/r 
concentrations, and LPV/r may increase the 
carbamazepine concentrations in plasma through the 
CYP3A4 pathway [14], [24], [30], [31].
Management
Consider alternative medications and monitor 
plasma concentrations of carbamazepine [14], [17]. An 
increment in LPV/r may be required [17]. Once-daily 
administration of LPV/r should be avoided [17], [18], [24].
Carbamazepine – ATV
Mechanism and consequence
Decreased plasma concentrations of ATV due 
to the induction of CYP3A4 isoenzyme, which may 
lead to viral resistance [14], [15], [17]. Carbamazepine 
concentrations may be increased through CYP3A4 
isoenzyme inhibition [14], [17].
Management
Coadministration should be avoided [15], [17], 
[18]; if the use of combination is necessary, plasma 
concentrations of carbamazepine should be monitored [17].
Valproate
Valproate – HCQ
There is no clinically significant interaction 
[14], [15], [19].
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Valproate – CQ
Mechanism and consequence
Seizure threshold may be decreased by 
CQ [15]. According to some other references, no 
clinically significant interaction was found [14], [19], 
[22].
Management
Use CQ with caution in patients with 
seizures [15].
Valproate – LPV/r
Mechanism and consequence
The combination increases the AUC of LPV 
by up to 38%. Valproate serum concentrations are 
decreased through induction of CYP450 enzymes, 
especially glucuronosyltransferases [15], [17], [18], 
[22], [24], [32], [33].
Management
Monitor clinical response and serum levels of 
valproate [14], [17], [18], [22].
Valproate – ATV
Mechanism and consequence
ATV may decrease serum levels of valproate 
[14], [18]. Some other studies did not report this 
interaction [17], [19], [22].
Management
Clinical response and serum concentrations of 
valproate should be monitored [14], [18].
Lithium
Lithium – HCQ/CQ/LPV/r
Mechanism and consequence
Lithium and CQ/HCQ/LPV/r can prolong 
QT interval, especially in patients with underlying 
cardiovascular disease or electrolyte abnormalities 
[15], [19].
Management
Correction of electrolyte abnormalities 
and monitoring symptoms of QT prolongation is 
required [15].
Lithium – ATV
No clinically significant interaction was found 
[14], [15], [19], [22].
Lamotrigine
Lamotrigine – HCQ
There is no clinically significant interaction 
[14], [15], [19], [22].
Lamotrigine – CQ
Mechanism and consequence
CQ-induced seizure may occur [15], [16]. 
Other references indicated no significant interaction 
[14], [19], [22].
Management
Use CQ with caution in patients with a history 
of seizures [15], [16].
Lamotrigine – LPV/r
Mechanism and consequence
The glucuronidation of lamotrigine enhances 
by LPV/r [14], [15]; thus, the lamotrigine AUC and half-
life reduce by 50% [14], [17], [18], [24], [34].
Management
The lamotrigine dose increment may be 
needed [17], [18], [22].
Lamotrigine – ATV
Mechanism and consequence
ATV may decrease the lamotrigine AUC up to 
12%, but it is not clinically significant [22], [35].
Management 
Monitor serum levels of lamotrigine. 
Approximately all references recommended no need 
for dose adjustment [14], [15], [17], [18], [19], [22].
Discussion
Physicians, psychologists, pharmacologists, 
pharmacotherapists, and other drug experts are 
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at the forefront during the COVID-19 pandemic. 
Pharmacological consultants were always needed 
hospital care procedures [36]. Furthermore, to provide an 
up to date information for public and specialists population, 
application of pharmacokinetic and pharmacodynamic 
investigations, especially during clinical trials, is essential 
[37], [38]. In this regard, the study of drug interactions 
is an important pharmacological preventive procedure 
to manage multiple drug consumption consequences. 
Hence, assessing drug-drug interactions with particular 
focus on psychiatric medications during the COVID-19 
pandemic is highly vital, while many patients in different 
age categories suffer from mental disorders, and their 
conditions have worsened due to the current situation, 
especially during quarantine and isolation.
More than 300 clinical trials on various 
therapeutic approaches are ongoing for COVID-19 [15]. 
Some of the tested medications, in this case, are 
highly potential for interacting with individuals’ chronic 
treatments. These interactions mostly appear due 
to pharmacokinetic features such as induction/
inhibitory effects on cytochrome isoenzymes and renal 
excretion, or pharmacodynamic properties such as 
QT prolongation. Furthermore, due to the extensive 
inflammation in COVID-19 patients, the pharmacokinetic 
performance of the drugs can be affected through organ 
dysfunction, CYP isoenzymes downregulation, plasma 
proteins modification, etc. [39], [40], [41].
Hence, psychiatric drug interactions with 
experimental agents administered for COVID-19 
should be considered carefully. Interactions between 
psychotropic drugs and drugs used for the treatment 
of COVID-19 have a wide range of severity from slight 
changes in the plasma level of the affected drug to life-
threatening conditions [42]. Thus, it was essential to 
prepare a detailed list of all widely used medications in 
such patients to improve outcomes and prevent adverse 
drug reactions and drug-drug interactions. We hope the 
list provided in this review helps the clinical care staff in 
treating such patients during the COVID-19 pandemic.
Conclusion
Knowledge about SARS-CoV-2 infection is still 
evolving. There are various projected medications for 
COVID-19 patients, which might be used in individuals 
under other chronic treatments, especially patients with 
mental disorders. Concomitant consumption of these 
medications may lead to drug interactions and acute 
adverse effects on the patient’s outcome. However, 
the risk of such interactions can be manageable 
through an ample knowledge of pharmacokinetic and 
pharmacodynamic regarding these drugs. Eventually, 
safe treatment in these patients could be managed 
by applying measures such as close monitoring, 
dosage adjustment, and considering relative/absolute 
contraindications and indications.
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